D. Boral Capital Reaffirms “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $46.00 price objective on the biotechnology company’s stock. D. Boral Capital’s price objective suggests a potential upside of 348.34% from the company’s current price.

A number of other brokerages have also commented on AVXL. HC Wainwright reaffirmed a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a research report on Friday, August 22nd. Wall Street Zen downgraded Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 23rd. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Anavex Life Sciences has an average rating of “Buy” and a consensus price target of $44.00.

Anavex Life Sciences Trading Up 9.7%

NASDAQ:AVXL opened at $10.26 on Wednesday. The stock has a 50 day simple moving average of $10.56 and a 200 day simple moving average of $9.30. Anavex Life Sciences has a 1-year low of $4.93 and a 1-year high of $14.44. The stock has a market cap of $881.23 million, a P/E ratio of -18.00 and a beta of 0.83.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, sell-side analysts forecast that Anavex Life Sciences will post -0.69 EPS for the current year.

Institutional Trading of Anavex Life Sciences

Several large investors have recently bought and sold shares of AVXL. Delta Asset Management LLC TN lifted its holdings in shares of Anavex Life Sciences by 9.1% during the second quarter. Delta Asset Management LLC TN now owns 12,000 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 1,000 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Anavex Life Sciences by 1.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 85,990 shares of the biotechnology company’s stock valued at $793,000 after acquiring an additional 1,233 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Anavex Life Sciences by 22.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 8,535 shares of the biotechnology company’s stock worth $79,000 after buying an additional 1,559 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,708 shares during the period. Finally, SeaCrest Wealth Management LLC lifted its stake in Anavex Life Sciences by 11.9% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 19,700 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 2,100 shares in the last quarter. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.